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Abstract: Photodynamic therapy (PDT) is a cancer treatment with a long-standing history. It employs
the application of nontoxic components, namely a light-sensitive photosensitizer and visible light,
to generate reactive oxygen species (ROS). These ROS lead to tumor cell destruction, which is
accompanied by the induction of an acute inflammatory response. This inflammatory process sends
a danger signal to the innate immune system, which results in activation of specific cell types and
release of additional inflammatory mediators. Activation of the innate immune response is necessary
for subsequent induction of the adaptive arm of the immune system. This includes the priming
of tumor-specific cytotoxic T lymphocytes (CTL) that have the capability to directly recognize and
kill cells which display an altered self. The past decades have brought increasing appreciation for
the importance of the generation of an adaptive immune response for long-term tumor control
and induction of immune memory to combat recurrent disease. This has led to considerable effort
to elucidate the immune effects PDT treatment elicits. In this review we deal with the progress
which has been made during the past 20 years in uncovering the role of PDT in the induction of the
tumor-specific immune response, with special emphasis on adaptive immunity.
Keywords: photodynamic tumor therapy; tumor-specific immunity; antitumor immunity, regulatory
T cells; dendritic cells; memory
1. Introduction
Photodynamic therapy (PDT) is a cancer treatment modality, for which the principle had
already been proposed over a century ago [1]. It is an alternative treatment among the currently
available therapies that offers minimal side effects for the patient while maintaining high efficiency [2].
As a clinically approved therapy it is used for the treatment of early staged disease and superficial
cancer types, and as palliative easement in terminal/late staged cancers [3,4]. PDT utilizes a
light-sensitive photosensitizer (PS), which is applied systemically or locally, and visible light of
appropriate wavelengths to excite the PS. After tumor-selective accumulation, the photosensitizer
is locally photoactivated by nonthermal light irradiation; subsequently it either emits fluorescence
light (diagnostic use), or reacts with surrounding molecules. In the presence of molecular oxygen,
reactive oxygen species (ROS) are formed, which oxidize proteins and lipids in the target cells.
This leads to stimulation of signaling processes as well as target destruction by apoptotic and necrotic
cell death (therapeutic use) [3,5]. Indirect effects leading to tumor cell destruction include vascular
shutdown by damaging endothelial cells and the vascular basement membrane. This results in blood
flow stasis, tissue hemorrhages, and oxygen deprivation. Furthermore, induction of an inflammatory
response and immune reactions directed against the tumor contribute to fighting off primary as well
as secondary disease manifestations [6]. However, PDT still constitutes more of a fringe option than
a regular treatment for cancer patients. This might be attributed to several limitations PDT faces:
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obviously, applicability is restricted by tumor site accessibility and penetration depth of light needed
to excite the photosensitizer. This limits therapeutic success, mainly to outer and inner body surfaces
and flat tumors. In addition, classical PDT is only suited for solid tumors. Tumor cells circulating in
the vasculature cannot be treated using traditional PDT protocols. During the past years, efforts have
been made to develop advanced protocols that overcome these disadvantages. Interstitial PDT using
optical fibers as light source and self-illuminated PDT show promising results for the treatment of solid
tumors of larger size (as compared to flat tumors) and for solid lesions in parenchymal organs. For
eradication of circulating tumor cells, efforts are being made to develop extracorporeal PDT protocols
which employ an antibody-conjugated PS to target specific cells, and illumination of the blood is
conducted afterwards [7–9]. Most advantageous—and currently under extensive research—is the
induction of antitumor immune reactions by PDT. These reactions serve to support primary tumor
elimination and to extend the local antitumor response to systemic surveillance to combat disease
recurrence, metastases, or circulating tumor cells [10]. This has even led to several approaches to use
PDT as vaccine [11,12]. In this review we focus on a collection of findings related to PDT-mediated
tumor-specific immunity and their implications for future directions in the field of photodynamic
tumor therapy.
2. PDT and Innate Immunity
The local trauma inflicted by PDT treatment on the tumor cells, the vasculature, and the
surrounding tissue causes induction and release of various mediators leading to an inflammatory
reaction to initiate an immune response. The oxidative stress due to the excessive generation of ROS
results in surface expression and secretion of damage-associated molecular patterns (DAMPs) as well
as inflammatory mediators which are released from dying and damaged cells. DAMPs are molecules
derived from host cells to signal cell injury or death. They predominantly comprise nuclear or cytosolic
proteins which become released from the cell or exposed on its surface and serve in the initiation of a
noninfectious immune response. Recognition of DAMPs via engagement with their respective receptors
on infiltrating immune cells (so-called pattern recognition receptors, PRRs) aids in signaling the nature
of the underlying threat to the immune system and enabling the appropriate immune response.
DAMPs reported to be necessary for the generation of antitumor immunity and induced upon PDT
include surface calreticulin (CRT), heat shock protein (HSP) 70, HSP90, ATP, and high-mobility
group box 1 protein (HMGB1) [13,14]. Inflammatory mediators include cytokines and chemokines.
Cytokines are small, secreted proteins produced mostly by immune cells, but also by endothelial
and stromal cells as well as fibroblasts. Their main function is to promote or inhibit proliferation,
activation, and differentiation of immune cells, thus they are commonly divided into proinflammatory
and anti-inflammatory or immunosuppressive cytokines. Prominent examples for proinflammatory
cytokines are interleukin (IL)-12 and IL-4, which are necessary for the differentiation of T helper
cells type 1 (Th1) and type 2 (Th2), respectively. Classical anti-inflammatory or immunosuppressive
cytokines include IL-10 and transforming growth factor (TGF)-β. IL-10 effectively inhibits expression
of Th1 cytokines and major histocompatibility complex (MHC) II and macrophage activation. TGF-β
inhibits cell proliferation and induces differentiation of regulatory T cells (Treg), an immunosuppressive
subtype of T helper cells. Chemokines are small cytokines which build up gradients in the affected
area and serve as chemoattractants. They are essential for directing the migration and activation
of phagocytes and lymphocytes in the course of an inflammatory reaction. Guided by chemotactic
gradients, inflammatory immune cells enter the affected region to launch an immune reaction and
remove the source of the threat.
2.1. Cytokine Release
Elevated levels of a variety of cytokines have been shown in animal as well as human studies.
Increased production of IL-6 appears to be a frequent event after PDT [15–19]. IL-6 is considered
to be a proinflammatory cytokine which stimulates the immune response, the induction of fever,
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and acute-phase proteins. However, results on the impact or function of IL-6 in PDT outcome differ.
In a system of EMT6 tumors treated with Photofrin®-PDT, blocking of IL-6 with respective antibodies
significantly reduced PDT-induced neutrophilia at 2 hours and 8 hours post-treatment [20]. Contrasting
this, another study found no effect of anti-IL-6 treatment on intratumoral neutrophil levels after
PDT [16]. Those contradictory findings may be attributed to the different photosensitizers used,
evaluation of blood neutrophil levels vs intratumoral neutrophil numbers, and different treatment
protocols and evaluation time points. Another prominent cytokine elevated after PDT is IL-1β.
In a model of rat rhabdomyosarcoma it was shown that increased IL-1β preceded PDT-induced
neutrophilia [21]. In subsequent studies, other groups were able to demonstrate that IL-1β is indeed a
crucial mediator in PDT outcome and neutrophilia since blocking of this cytokine led to a significantly
decreased rate of tumor cures and neutrophils in the tumor-draining lymph nodes (TDLN) in response
to treatment [22,23]. Other cytokines that have been reported to be elevated post PDT include tumor
necrosis factor (TNF)-α and interferon (IFN)γ [10]. The chemokines CXCL1 (chemokine (C-X-C)
ligand 1 or keratinocyte chemoattractant, KC) and CXCL2 (macrophage inflammatory protein-2,
MIP-2) were also shown to be increased after PDT treatment in a murine model of EMT6 carcinoma.
These two chemokines are known for possessing neutrophil chemoattractant activity. However, only
CXCL2 was shown to be necessary for neutrophil migration into the tumors in this setting [16].
In a rather recent report, Brackett et al. found induction of the cytokine IL-17 after treatment.
This cytokine proved its importance by acting upstream of IL-1β to regulate its expression levels.
Thereby, it indirectly controlled the expression of CXCL2 which was dependent on IL-1β. Diminished
levels were found for TGF-β in the sera of CT26 colon carcinoma-bearing mice after PDT treatment
with benzoporphyrin derivative (BPD) [24]. Additionally, blockade of immunosuppressive cytokines
TGF-β and IL-10 has been shown to greatly enhance PDT-mediated tumor cure rates in C3H/HeN
mice with subcutaneous FsaR fibrosarcomas [25].
2.2. Neutrophils
The importance of neutrophils in PDT efficiency has been proven in numerous studies.
Neutrophils pose the first line of defense against pathogens and inflammatory insults to the host.
In order to do so they secrete leukotrienes, prostaglandins, and cytokines to initiate the development
of the inflammatory response. Furthermore, they are able to directly kill pathogens and they have
been reported to be able to present antigens via MHC class II under certain circumstances. This raises
the possibility that neutrophils could aid in the activation of CD4+ T helper cells. Increased levels of
neutrophils following PDT have been reported frequently [22,23,26–28]. Moreover, Korbelik et al.
showed that depletion of neutrophils led to a drop in mice cured from EMT6 tumors to 30%,
with tumors recurring after 2–3 weeks [29]. In line with this are findings from Kousis and coworkers
demonstrating that neutrophil depletion resulted in diminished numbers of activated cytotoxic T
lymphocytes (CTL) in the TDLN and the tumor tissue [30]. In a different approach using blockade of
neutrophil migration by administering anti-ICAM1 (intercellular adhesion molecule 1) the group of Sun
demonstrated complete abrogation of the curative outcome of their treatment regimen. Additionally,
this work showed an impairment of the curative effect following administration of anti-IL-1β [22].
This finding was further highlighted by studies from Brackett et al. [23]. In their setting, neutrophil
entry into TDLN post-PDT was mediated by CXCR2–CXCL2 interaction, with CXCL2 induction being
dependent on IL-17A and IL-1β. Interestingly, the degree of neutrophil infiltration appears to be
governed by the treatment regimen applied. Work from Shams et al. revealed that the highest degree
of neutrophil influx into tumor tissue and TDLN was achieved with a treatment regimen delivering a
low fluence at a low fluence rate. This was further accompanied by a substantial increase in activated
CTL [31]. A previous study already demonstrated the highest degree of induction of proinflammatory
cytokines IL-6, MIP-1, and MIP-2 under these treatment conditions compared to regimens delivered at
higher fluence and/or higher fluence rate [19].
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2.3. Dendritic Cells
Crucial for the induction of an adaptive immune response are dendritic cells (DCs). DCs are
professional antigen-presenting cells (APC) and as such their main function is to present endogenous
(e.g., viral) as well as exogenous (e.g., bacterial) antigens to lymphocytes in order to activate them
and mount an appropriate immune response. They exist in two functionally distinct stages, “mature”
and “immature”. Immature DCs constantly sample their environment by taking up antigens via
macropinocytosis, receptor-mediated endocytosis, and phagocytosis. They are characterized by
expression of CD11c and low levels of MHC I, MHC II, CD80, and CD86 and the relative absence of
cytokine production. In the presence of inflammatory stimuli, those immature DCs differentiate into
their mature state. This includes upregulation of processing and presentation of antigens and increased
expression of MHC molecules and the costimulatory molecules CD80 and CD86. Additionally,
maturation induces secretion of proinflammatory cytokines including IL-12, IL-6, and IL-1β. Mature
DCs migrate to the lymph nodes in large numbers where they present peptide–MHC complexes to
lymphocytes. In combination with appropriate costimulation, this leads to activation of CD4+ T helper
cells, CD8+ CTL, and B cells, and initiates the adaptive immune response [32,33].
Several groups have shown the importance of DCs for PDT-mediated antitumor immunity and
efficiency. Jalili and coworkers were able to demonstrate that intratumoral injection of immature
DCs after PDT treatment resulted in significantly delayed tumor growth of the treated tumor and of
untreated tumors in the contralateral hind limb [34]. Similar outcome was reported by the group of
Saji [35]. Further corroborating these findings were experiments by Preise et al.: DTR bone marrow
chimera mice were inoculated with CT26 colon carcinoma cells, and subcutaneously growing tumors
were subjected to PDT. Depletion of DCs by injection of diphtheria toxin (DTx) resulted in increased
recurrence rates of the tumors. Mice which were systemically depleted of DCs showed 90% of disease
recurrence compared to only 20% in mice which received PDT treatment only [36]. Furthermore,
other reports support the involvement of DCs in the response to PDT as evidenced by enhanced
maturation and activation as well as increased secretion of proinflammatory cytokines after
treatment [37–40].
3. PDT and Adaptive Immunity
The first evidence for induction of a tumor-specific immune response following PDT came from
Canti et al. in 1994. This group demonstrated that normal mice cured from MS-2 fibrosarcoma by
PDT were able to resist a rechallenge with tumor cells in a tumor-specific manner. In contrast to
this, immunosuppressed counterparts were not able to resist the rechallenge [41]. Since then, several
studies have shown that an intact immune system—specifically the adaptive arm of the immune
response—is crucial for PDT outcome. Korbelik et al. demonstrated that treatment of BALB/c mice
bearing EMT6 mammary carcinomas with PDT resulted in complete cures, whereas SCID mice did not
elicit the same antitumor response with the identical PDT regimen [27]. Since SCID mice lack mature T
lymphocytes, they are not able to mount a cellular adaptive immune response. Likewise, the group of
Preise successfully treated BALB/c mice with a vascular-targeted PDT approach from CT26 tumors
with cure rates of more than 70%. When the same experiments were carried out in BALB/nude or
SCID mice, cure rates dropped to 18% and 11%, respectively [36]. Similar findings were repeatedly
reported from other groups as well over the years [10,42,43].
Induction of systemic and memory immunity following PDT treatment has also been verified in
numerous studies. Systemic immunity is reflected by the extension of the locally induced immune
response to distant nontreated areas. A study by Kabingu and coworkers demonstrated the destruction
of lung metastases indicative of an ongoing systemic immune response: mice were inoculated
subcutaneously (s.c.) and intravenously (i.v.) with EMT6 tumor cells to generate a primary tumor (s.c.)
and lung tumors mimicking metastases (i.v.). Treatment of the primary tumor with Photofrin®–PDT
led to 90%–100% of tumor ablation, and analysis of lung metastases 10 days after PDT revealed a
significant reduction of lung tumors compared to nontreated controls [42]. Likewise, Mroz et al.
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reported regression of distant untreated tumors. In their model, mice bearing bilateral s.c. CT26.CL25
tumors were treated with BPD–PDT on one side while the contralateral tumor was left untreated.
In a total of seven out of nine mice, this approach led to complete and permanent regression of the
contralateral tumor [10]. Recent publications by other groups further support those findings [31,43].
Additionally, clinical observations report the regression of lesions outside the treatment field after
PDT-treatment as well, thus indicating the generation of systemic immunity in human patients [44–46].
Recurring disease can only be prevented when memory immunity is successfully generated.
In experimental models of cancer, generation of such a memory immunity can be evaluated by
resistance of previously cured subjects to rechallenge with the same type of cancer cells. The first study
indicating the induction of tumor-specific immune memory was published by Korbelik et al. in 1999:
this work showed the ability of SCID mice to resist tumor cell rechallenge after they were cured from
EMT6 tumors by a combination approach of adoptive transfer of tumor-sensitized splenocytes and
PDT treatment [47]. The group of Preise demonstrated long-lasting protection against rechallenge
in immunocompetent mice cured from primary tumors using a vascular-targeted approach of PDT.
Interestingly, this approach even resulted in partial cross-protection against a different type of tumor
cell used for rechallenge. However, the mechanism underlying this observation still remains to be
elucidated [36]. In another study by Sanovic et al., BALB/c mice bearing a s.c. CT26 colon carcinoma
were treated with hypericin–PDT, and this treatment yielded a striking 100% of tumor cures, which
lasted until the end of the study. Additionally, i.v. challenge of those cured mice with viable CT26
cells showed no development of new tumors, thereby indicating existence of systemic memory
immunity. Notably, these results were obtained with a protocol using a low PS dose delivered at a low
fluence and low fluence rate [48]. Similar findings were reported by Mroz et al. who demonstrated
95% of cured mice resisting tumor development upon subsequent rechallenge [10]. Reginato and
coworkers achieved 90% of cures with a treatment protocol employing BPD and Treg depletion using
cyclophosphamide in a CT26 tumor model. Sixty-five percent of these mice rejected the rechallenge.
However, with this protocol, another round of Treg depletion prior to rechallenge was necessary to
unravel the memory immunity [24]. Interestingly, this group used the same type of tumor model
(CT26 colon carcinoma in BALB/c mice) as Sanovic et al., whose studies showed no requirement for
Treg depletion for therapeutic success. These differences might be attributed to the use of different
PS (hypericin vs BPD) and/or differences in fluence and fluence rate (14 J cm−2@27 mW cm−2 vs.
120 J cm−2@100 mW cm−2). Other groups assessed induction of memory immunity by resistance to
rechallenge as well and reported results in line with the abovementioned findings [31,43].
The mediators of the adaptive immune response are antigen-specific B and T cells. Upon antigen
recognition, B cells produce the antibodies necessary for eliminating extracellular pathogens. Although
there are pieces of data pointing to a role for B cells in PDT-induced antitumor immunity [27,36,43],
the importance of this humoral response has remained largely uninvestigated. In contrast to that,
considerable efforts have been made over the past two decades to elucidate the role of the cellular
immune response, i.e., the role of T lymphocytes. The findings regarding this population will be
discussed in the following sections.
3.1. CD4+ T Cells
T cells are divided into several subpopulations. When activated, CD4+ T helper cells differentiate
into distinct lineages, a process which is dependent on the stimuli and cytokines present. Those
lineages secrete defined cytokines to assist in clearance of intracellular pathogens and extracellular
microorganisms. Furthermore, CD4+ T helper cells provide help for B cells and CD8+ cytotoxic T cells
for their activation and the generation of memory cells. The best defined T helper cell populations
are Th1, Th2, and Th17. Th2 cells and their associated cytokines—IL-4, IL-5, and IL-13—serve in the
response to extracellular microorganisms and the induction of the B cell isotype switching. Th1 cells are
characterized by production of IFNγ and are crucial for the eradication of intracellular pathogens. IFNγ
is known to activate the bactericidal activity of macrophages and increase the expression of MHC I on
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normal cells and MHC II on APCs. Thereby it facilitates processing and presentation of endogenous
antigens, which makes infected and aberrant cells visible to the immune system. Furthermore, IFNγ
promotes activity of natural killer (NK) cells, which recognize and eliminate cells with decreased MHC
I expression. Th1 cells have implications in antitumor immunity via activation and regulation of CTL,
cross-priming of the immune response by APCs (this enables presentation of intracellular antigens
in the context of MHC II), and direct tumor cell-killing through the release of specific cytokines [49].
The third subtype of T helper cells, that is well established by now, are Th17 cells and their signature
cytokine IL-17. IL-17 leads to stimulation and de novo generation of neutrophils and is important
in the response to certain extracellular bacteria and fungi [50]. In cancer, Th17 cells seem to be able
to have opposing roles. There are numerous reports showing eradication of tumors by Th17 cells
and a beneficial effect of their abundance in the tumor microenvironment. However, an equally
solid body of evidence suggests a role for this subpopulation in tumor progression. This opposing
impact of Th17 cells on tumor immunity seems to be attributable to the fact that the fine-tuning
of their differentiation and function is highly dependent on a variety of factors; these include the
type of tumor, the composition of stimuli leading to their activation (e.g., cytokine composition,
T cell receptor signaling strength) and the therapeutic approach applied [51]. Interestingly, Th17
cells share ties with immunosuppressive Treg. In a proinflammatory environment, the decision of
whether naïve T cells develop into either Treg or Th17 is dependent on the amount of available TGF-β:
at low concentrations it synergizes with IL-6 and/or IL-21 and drives the induction of Th17 cells.
At high TGF-β concentrations these cytokines are no longer sufficient to overcome Foxp3 (forkhead box
protein 3)-mediated repression of retinoic acid receptor (RAR)-related orphan receptor (ROR)γt, and
the cells differentiate into Treg [52]. Additionally, Th17 cells are able to acquire a Th1-like phenotype
with the ability to secrete IFNγ when they are exposed to IL-12 [51]. The role of T helper cells in
PDT-mediated immunity is somewhat controversial. Experiments by Kabingu et al. showed no
effect of CD4+ T cell depletion on PDT efficiency and induction of systemic antitumor immunity [42].
In contrast to that, other groups found a dependency of treatment outcome on the presence of CD4+
T cells. The group of Korbelik used antibodies for CD4, CD25, and a combination of both to deplete
T helper cells, and saw a drop in cures by 30%–50% [29,47]. In line with this are results from others
reporting delayed or abrogated tumor growth in naïve mice following adoptive transfer of CD4+
T cells from PDT-cured mice. Further analysis of this CD4+ population showed increased IFNγ
secretion upon restimulation, which is indicative for the generation of a Th1 response [36]. However,
the precise mechanisms by which CD4+ T cells contribute to PDT outcome remain largely elusive so far.
Some light on this was shed by Brackett and coworkers, who showed an increase of Th17 cells and the
corresponding signature cytokine IL-17A in the tumor-draining lymph nodes after PDT treatment [23].
In a very recent work Garg et al. found elevated levels of Th1 and Th17 cells in the brain immune
contexture of mice treated with an immunogenic cell death (ICD)-based DC vaccine against high-grade
glioma (HGG) and subsequently inoculated with the respective glioma cells. Furthermore, splenic
T cells from these mice exhibited higher IFNγ production upon restimulation with naïve GL261 cell
lysates, thus indicating expansion of localized immunostimulation in the brain to a systemic effect
crucial for long-term immunity [14].
3.2. CD8+ T Cells
CD8+ CTL are essential for recognition and elimination of cells that are virally infected or display
aberrant self. CTL recognize intracellular peptide bound to MHC class I on the cell surface, and upon
activation they exert direct cytolytic effects against the target cell accompanied by the secretion of
IFNγ. First evidence for the involvement of CTL came from Korbelik et al. in 1999. This group used
an EMT6 mammary carcinoma model in which depletion of CD8+ T cells led to a 50% decrease in
cures after PDT compared to unmanipulated mice [47]. Similar results were obtained by different
groups using 2-iodo-5-ethylamino-9-diethylaminobenzo-phenotiazinium chloride or Photofrin® as
photosensitizers, albeit Photofrin® was used in a combination approach with 5-aza-2’-deoxycytidine
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to induce the tumor antigen P1A [53,54]. However, presence of P1A was not necessary to sustain
long-term immunity. Likewise, adoptive transfer of CD8+ lymphocytes from cured animals was
sufficient to protect naïve recipients from subsequent challenge with viable cancer cells from the same
type [36,54]. It should be noted that this protection did not show a requirement for additional transfer
of CD4+ T helper cells. A study by Saji et al. further substantiates these finding with an experiment
where the transfer of CD8+ T cell-depleted splenocytes from PDT-cured mice into naïve recipients
conferred protection to rechallenge [35]. Other studies frequently found elevated levels of CD8+ T
cells after treatment, and closer examination of those cells revealed increased lytic activity against
tumor cells in an antigen-specific manner [10,30,31]. On a clinical level, Abdel-Hady et al. were able to
show that patients with vulval intraepithelial neoplasia who responded to PDT had increased levels of
infiltrating CD8+ T cells after treatment [55].
3.3. Regulatory T Cells
Regulatory T cells comprise a unique subset among the CD4+ T cell subpopulations. Treg cells
display regulatory and suppressive activity towards other immune cells, and especially effector T
cells. On the molecular level they are characterized by the constitutive expression of high levels of the
transmembrane protein CD25 (IL-2R α chain) [56] and cytotoxic T lymphocyte-associated antigen 4
(CTLA-4) [57] and stable expression of the lineage-specific transcription factor Foxp3 [58,59]. By now,
it is well established that Treg are required for immunological tolerance and prevention of excessive
inflammatory immune responses. Neonatal thymectomy in mice results in fatal T cell-mediated
autoimmunity against various organs due to the lack of regulatory T cells [60]. Mutations in the
X chromosome-encoded Foxp3 gene, as in human IPEX patients and Scurfy mice, leads to severe
immune dysregulation, polyendocrinopathy, and enteropathy related to an inability to generate Treg
and establish tolerance [59,61]. Their origin is either in the thymus (tTreg) in response to recognition of
self-antigen during negative selection or in peripheral lymphoid organs (pTreg), where naïve T cells
recognize antigens in a tolerogenic environment—like that of commensal bacteria in the gut or the
cancer microenvironment—and differentiate into pTreg. tTreg are considered to provide tolerance
towards self-antigens that are represented in the thymus, whereas the main function of pTreg is the
establishment of tolerance to antigens that are either foreign but not harmful or self-antigens not
presented in the thymus during T cell development [62,63]. In cancer it has been shown that Treg are
the predominant T cell type accumulating in tumor tissue, and low T effector/Treg ratios correlate
with poor prognosis in various tumor types [64–66]. Regulatory T cells employ various mechanisms to
suppress effector T cells. Those mechanisms include sequestration of available IL-2 via the high affinity
IL-2 receptor, CTLA-4 (CTL-associated protein 4)-mediated sequestration of CD80/86 on APC surfaces,
production of inhibitory cytokines like IL-10 and IL-35, production of pericellular adenosine, and
direct cytolysis of effector T cells by granzyme B and perforin [67]. In the tumor microenvironment,
Treg keep effector T cells in an intermediate state via sequestration of IL-2 and production of TGF-β.
Withdrawal of IL-2 prevents full activation of effector T cells and ensures continuous availability
of IL-2 produced by partially activated T cells, which Treg need for their maintenance but do not
produce themselves [68]. TGF-β prevents full cytotoxic effector differentiation of tumor-specific CD8+
T cells and keeps memory CD8+ T cells in an inactive state [69,70]. The importance of suppression of
Treg to increase PDT efficiency has recently been shown in several studies [24,71]. Treg depletion by
cyclophosphamide followed by PDT in mice bearing CT26 colon carcinomas led to improved long-term
survival and development of memory immunity [24]. It should be mentioned that this need for Treg
depletion constitutes sort of a conundrum: lymphocytes have been shown to be especially sensitive to
PDT-mediated cell death (see below). Therefore, Treg residing in the tumor microenvironment should
be depleted by PDT treatment, thus abolishing the need for external depletion. However, other studies
using the same tumor model did not show this requirement. Although there have been substantial
differences in the treatment protocols between those studies, the reason for this particular aspect
has (to the best of our knowledge) not been addressed so far and clearly needs further elucidation.
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A recent study from Garg and coworkers looking at the brain immune contexture in a murine model
of HGG showed a shift from Treg towards Th1/Th17/CTL following treatment with an ICD-based DC
vaccine in a prophylactic as well as in a curative setting [14]. Zheng et al. found a decrease of Treg
induction in vitro and in vivo in response to stimulation/treatment with DC which had been pulsed
with PDT-treated Lewis lung carcinoma cells (LLC). This was accompanied by a significant inhibition
of tumor growth upon challenge with live LLC cells [40]. In a clinical setting, blood analysis of patients
with esophageal squamous cell carcinoma demonstrated that PDT with the PS Photofrin® abolished
the suppressive function of peripheral Treg, but had no effect on Treg numbers [72]. Taken together,
these studies indicate effects of PDT on Treg, which have to be elucidated in order to harness the
potential of PDT to break tumor-promoting immune suppression.
4. Treatment Regimen and Modes of Cell Death
There are still considerable differences in treatment outcomes, limiting the successful translation
of PDT into broad clinical application. These differences might be attributed to a variety of parameters
including the PS and PS dose used, the drug–light interval, the applied fluence and fluence rate,
and the light source itself.
One determinant of the induction of antitumor immunity is the mode of cell death, which is
triggered by the applied treatment regimen and can be influenced by any of the parameters mentioned
above. An extensive review about the modes and mechanisms of cell death in PDT induced by
different PS was published by Bacellar et al. in 2015 [73]. In general, PDT is able to result in apoptosis,
necrosis, the so-called immunogenic cell death (ICD), and autophagy. Apoptosis is traditionally
considered as a programmed form of cell death which is immunologically silent. The remnants of
these “physiologically” dying cells are quickly removed afterwards by phagocytes. Therefore, cells
undergoing apoptosis normally do not elicit a strong immune response or a detectable response at all,
for that matter. In contrast to that, necrosis is the result of an insult or trauma that leads to rapid cell
death. This form of cell death characteristically involves the uncontrolled release of cellular products
and the initiation of an inflammatory response in the surrounding tissue, which can lead to severe
bystander damage. Although an inflammatory response is necessary for the induction of the immune
response, this process can be detrimental for the host when it cannot be resolved by the immune
system. In light of these definitions, one would assume that necrotic cells or a mixture of necrotic and
apoptotic cells should be more efficient in facilitating the development of a distinct immune response
than apoptotic cells. Contrasting this, there are numerous reports demonstrating that apoptotic cells
are superior to necrotic cells in inducing antitumor immunity [74–80]. Intensive research in the field of
cell death in the following years led to the fairly new concept of ICD. ICD describes an immunogenic
form of apoptosis or necrosis. Since the emergence of the concept of ICD it has been shown that tumor
cells undergoing immunogenic apoptosis are more potent inducers of antitumor immune responses
than cell dying via necrosis or nonimmunogenic apoptosis. Thus, it would be favorable to use and
develop PSs which predominantly cause ICD in cancer cells for future approaches. Importantly, so
far hypericin is the only PS shown to induce all major molecular and immunological hallmarks of
ICD. This includes surface expression of CRT, HSP70, and HSP90 and secretion of ATP—four DAMPs
crucial in ICD [80,81].
In an elegant study, Garg et al. demonstrated remarkable prophylactic and therapeutic success
using DCs loaded with hypericin–PDT killed tumor cells in a model of HGG. In this case, the induction
of antitumor immunity was dependent on the PDT-induced surface exposure of CRT and release
of HMGB1 (amongst others). Notably, analysis of glioma cells treated with aminolevulinic acid
(ALA)–PDT revealed no significant increase of those two DAMPs [14]. This clearly shows that the
type of PS used can influence the determinants of cell death and its impact on subsequent antitumor
immunity. Treatment parameters regarding the applied fluence and fluence rate also differ greatly
among studies and have considerable effect on therapy outcome. It has been shown that at high-fluence
PDT predominantly causes necrosis, while at medium to low fluences apoptosis or a mixture of
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apoptosis and necrosis is more prevalent [82]. Analysis of neutrophilia and secretion of cytokines
(as a measure for inflammation) induced by different combinations of fluence and fluence rate by
Henderson et al. showed that the most inflammatory response was triggered at a low fluence and
a low fluence rate. However, the best tumor control was achieved with a high to intermediate
fluence at a low fluence rate. This regimen only caused mild inflammation [19]. In a subsequent
study, a sequential treatment approach consisting of a first session causing substantial inflammation
(low fluence, low fluence rate) followed by a second session for tumor control (high/intermediate
fluence, low fluence rate) yielded the best results with respect to control of the primary disease
and induction of memory immunity [31]. These results are backed from findings by others
indicating that low-dosed or vascular-targeted treatment regimens have better overall therapeutic
outcome [36,43,48,83]. Additionally, clinical reports support a beneficial effect for therapy when
using milder treatment protocols [45,84]. Another example for the impact of different treatment
regimens and the influence they can have on the therapeutic approach comes from comparison of
studies from Reginato et al. and Sanovic and coworkers: those two groups used the same tumor
model (i.e., subcutaneously growing CT26 tumors in BALB/c mice) but their treatment regimen
differed considerably in terms of PS (BPD vs hypericin) and in the fluence and fluence rate applied
(120 J cm−2@100 mW cm−2 vs. 14 J cm-2@27 mW cm−2). Still, both groups achieved tumor cures and
induction of memory immunity. However, in the system using BPD and a high light dose, depletion of
Treg was necessary to induce tumor-specific immunity and unravel memory immunity [24,48].
A different aspect of the PS dose used is the effect on surrounding immune cells. T lymphocytes
have been shown to be especially sensitive to PDT-induced death [85,86]. This might actually be
beneficial therapy outcome since most of the T cells within the tumor microenvironment are considered
to have an immunosuppressive phenotype. These T cells would be destroyed and the area would be
repopulated by activated effector T cells. Indeed, it has been shown that shortly after PDT treatment,
CD3+ lymphocytes (CD3 as part of the T cell receptor is expressed on all T cells) disappeared. About
24 h later, CD3+ T cells were present again with levels exceeding those prior to treatment [36,43].
Additionally, unpublished data from our group indicates that DCs show a higher susceptibility to
PDT-mediated cell death in a dose-dependent manner with a variety of PSs compared to several
different cancer cell lines tested. This raises the possibility that the PS dose used might affect antigen
uptake and presentation (due to enhanced killing of antigen-presenting cells) necessary for launching
the adaptive immune response.
5. Conclusions
The capability of PDT to effectively cure primary tumors and induce systemic and long-lasting
immunity to combat metastases and recurring disease has been shown in numerous studies and a
variety of settings over the past two decades. This holds the potential for this particular treatment
modality to become a powerful therapeutic option for cancer patients. Recent years have seen a
number of improvements to lift limitations given by the nature of PDT. Technical improvements
include the development of new light sources to reach solid tumors that are neither superficial nor
intraluminal. Furthermore, there are continuous efforts to develop PS which need less energy to be
properly excited. This enables the use of light with longer wavelength, which penetrates deeper into
tissue. Coupling of PS to antibodies specific for the tumor cells in question is supposed to improve
targeting of the PS to the tumor.
With increasing technical progress and improvements of PSs it should be possible to extend the
applicability of PDT to a point where it would be a feasible therapy option for a broad spectrum
of cancer entities. We believe that comparative analyses of the immunological effects elicited by
different parameters of PDT (e.g., PS type and dose, fluence and fluence rate) would greatly enhance
the understanding of the induction of antitumor immunity induced by this therapy. This would aid in
developing protocols which efficiently fight off the primary tumor and boost the immune system to
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recognize and combat distant and recurring disease manifestation while being patient-sparing, easy to
handle, and cost-effective.
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